# αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)

> **NCT06082947** · NA · RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Hematopoietic Stem Cell Transplantation
- Hematologic Malignancy

## Interventions

- **DEVICE:** CliniMACS®

## Key facts

- **NCT ID:** NCT06082947
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-18
- **Primary completion:** 2028-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06082947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06082947, "αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06082947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*